Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Jared Fink

Jared Fink Jared Fink is the firm’s pharmacovigilance specialist. He is a graduate of the College of Wooster and has a strong background in scientific research and writing. His full biography is here.

Posts by Jared Fink

Beginning of the End for Monsanto?

Posted in Lawsuits, Politics, Public Health

A former farm worker named Enrique Rubio may just be the right “David” to take down “Goliath” chemical company Monsanto. Rubio filed suit against the manufacturer of Roundup® early last week, claiming that the company’s infamous herbicide is the cause of his bone cancer and inability to work. Roundup’s® safety has been hotly debated for… Continue Reading

Postponement of Daubert Hearing in Zoloft Birth Defects Case

Posted in Uncategorized

U.S. District Judge Cynthia Rufe or the Eastern District of Pennsylvania made the only call she could on Tuesday: the postponement of Daubert hearing in Zoloft birth defects case until September. The multidistrict litigation (MDL) against Pfizer, claiming its popular antidepressant, Zoloft causes birth defects, came to a halt as the plaintiffs’ expert was disqualified… Continue Reading

Drugs Disapproved by the FDA Deserve Attention

Posted in Drug Studies, FDA Regulation, Public Health

Recently, Reuters reported that “Drug companies generally don’t disclose all the reasons new medicines fail to win U.S. marketing approval, even though regulators often reject treatments over concerns about safety or effectiveness”. Reporter Lisa Rapaport quotes Dr. Peter Lurie, FDA associate commissioner for public health strategy and analysis, saying “‘Only a minority of the press… Continue Reading

FDA: AndroGel, Low-T Drugs Must Warn for Heart Attack

Posted in Androgel

On Tuesday March 3rd, the United States Food and Drug Administration required that manufacturers of testosterone supplements (or, Low-T drugs)  include warnings on packaging for the increased risk for heart attack and stroke linked to these drugs. In years past, a great many peer-reviewed scientific studies had demonstrated that men using Low-T drugs were at… Continue Reading

Actos Manufacturer to Pay Millions in Cancer Lawsuit Settlement

Posted in Actos & Bladder Cancer

Last week, the pharmaceutical company, Takeda, was ordered to pay $1.3 million in punitive damages to a former Philadelphia schoolteacher who “argued the drugmaker’s Actos diabetes medicine caused his bladder cancer”, Japan Times writes. Only a few days earlier, that man was awarded over $2.3 million in compensatory damages. According to that Japan Times article,… Continue Reading

2012 – 50% of IVC Filters Fail

Posted in IVC Filters

In 2012 the Journal of the American Medical Association published an article titled “Frequent Fracture of TrapEase Inferior Vena Cava Filters,” providing further insight into one serious side effect related to the use of IVC filters. Inferior vena cava (IVC) filters are small metal filters placed within the vena cava vein used to trap blood… Continue Reading

IVC Filters: 86% Exhibit Serious Side Effects

Posted in IVC Filters

In 2012, a team of researchers from the Department of Radiology and Biomedical Imaging at the University of California, San Francisco published an article that illustrated some serious risks associated with the use of IVC filters. Inferior vena cava filters are small metal filters inserted into the inferior vena cava vein, used in patients with… Continue Reading

Xarelto lawsuits cite studies indicating higher risk for bleeding than Bayer reports

Posted in Xarelto

Titled “The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome”, a piece by A.C. Camuglia et al. (published in Current Medical Research and Opinion – August, 2014) from Royal Brisbane and Women’s Hospital and the University of Queensland (Queensland , Australia) reviews the safety of an anticoagulant drug… Continue Reading

Study shows Xarelto carries higher risk for bleeding than industry standard

Posted in Xarelto

Here, we discuss a study titled “Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.”, published in European Heart Journal this year by G. Breithardt and a team of German researchers.  This study aimed to further… Continue Reading

2014 – Researchers Cite Xarelto Bleeding Risk

Posted in Xarelto

Recently, studies have shown that the anticoagulant drug Xarelto (rivaroxaban) is linked to a dramatically increased risk for major bleeding events compared to other drugs in its class.  Here, we discuss one such piece of research, titled “New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments?”, published in the September,… Continue Reading

2014 – More Research Shows Xarelto Linked to Major Bleeding Events

Posted in Xarelto

In recent years, a number of studies have shown that the anticoagulant drug Xarelto (rivaroxaban) is linked to increased risk for major bleeding events.  Here, we discuss one such study, titled, “Anticoagulant-related gastrointestinal bleeding-could this facilitate early detection of benign or malignant gastrointestinal lesions?” and published in the August, 2014 edition of Annals of Medicine… Continue Reading

2014 – Study shows Xarelto more dangerous than other drugs in its class

Posted in Xarelto

Recently, the anticoagulant drug Xarelto (rivaroxaban) (Bayer Pharmaceuticals, Inc.) has been linked to an increased risk for major bleeding events, prompting a number of Xarelto lawsuits.  In August 2014, medical researcher Eugene Yang published a piece in Vascular Health and Risk Management titled “A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke… Continue Reading

2014 – Xarelto linked to higher risk for bleeding

Posted in Xarelto

In the United States alone, about four million prescriptions for anticoagulant drugs are filled each year.  With the use of each of these drugs comes the risk for internal bleeding, but not all drugs are created equal.  One such drug is Xarelto (rivaroxaban), and currently, the Xarelto Black Box Warning fails to adequately inform users… Continue Reading

2014 – FDA Recalls DePuy Craniomaxillofacial Distraction System, Cites Fatal Risk

Posted in Devices, FDA Regulation, Recalls

Recently, a craniofacial distraction implant by DePuy Orthopaedics was recalled.  This device, called the Craniomaxillofacial (CMF) Distraction System, “is a modular family of internal distraction devices that are used to gradually lengthen the mandible body and ramus” and indicated as “a bone stabilizer and lengthening (and/or transport) device for correction of congenital deficiencies or posttraumatic… Continue Reading

2014 – Birth defects risk increased 250% with Depacon / Depakene / Depakote

Posted in Depacon / Depakene / Depakote

In recent years, dozens of studies have been published illustrating an increased risk for birth defects linked to antiepileptic drugs containing sodium valproate such as Depacon, Depakene, and Depakote.  While these drugs are effective in the mitigation of seizures, the risks posed to developing babies cannot go overlooked.  Here, I will summarize one such study… Continue Reading

SSRIs linked to “abnormal development” of fetus

Posted in SSRI Birth Defects

In 2012, C.M. Nijenhuis and a team from University of Groningen (Groningen, The Netherlands) published a study titled “Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.” in British Journal of Clinical Pharmacology.  There, the link between gestational exposure to selective… Continue Reading

2009 – Preterm birth again linked to SSRI exposure before birth

Posted in SSRI Birth Defects

Recently, I found an article titled “Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.” that originally appeared in the December 2009 edition of American Journal of Obstetrics and Gynecology.  Published by R. Calderon-Margalit and a team from The University of Washington School of Public… Continue Reading

Risk for birth defects 47% higher with prenatal exposure to Depacon, Depakene, or Depakote

Posted in Depacon / Depakene / Depakote

In January of last year, a team of researchers led by E. Campbell published an article in Epilepsia titled “Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero.”, marking yet another piece of professional research illustrating the risks of prenatal exposure to drugs containing sodium valproate such as Depacon, Depakene, and… Continue Reading

Study shows: Depacon lifts risk for autism 300%

Posted in Depacon / Depakene / Depakote

Today, I found another article by G. Veiby and a team from The University of Bergen in Bergen, Norway that demonstrates the danger posed to children exposed to valproate in utero.  Valproate (sodium valproate, other formations) is the active chemical in a number of antiepileptic drugs such as Depacon, Depakote, and Depakene.  The article I… Continue Reading

2011 – Birth defect risk “significantly higher” with Depacon, Depakene, or Depakote exposure before birth

Posted in Depacon / Depakene / Depakote

In July, 2011, Lancet Neurology published an article titled “Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.” that was written by a team from Stockholm led by T. Tomson.  This study is yet another example of peer-reviewed research demonstrating that serious risks are posed to… Continue Reading

SSRIs in pregnancy linked to 12-fold increased risk for preterm birth

Posted in SSRI Birth Defects

Today, I came across an article published in a 2011 edition of Journal of Midwifery and Women’s Health by G. Latendresse and a team of researchers from The University of Utah College of Nursing (Salt Lake City) titled “Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm… Continue Reading